$0.00
(Market cap
$6 Mln
Recently Viewed
Clear AllMarket cap
$6 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.3
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-6.9 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-0.3
Debt to Equity
0.2
Book Value
$0.4
EPS
$-2.4
Face value
--
Shares outstanding
29,154,431
CFO
$-78.86 Mln
EBITDA
$39.46 Mln
Net Profit
$-175.21 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Eterna Therapeutics Inc (ERNA)
| -84.0 | -18.4 | -84.0 | -93.4 | -84.3 | -76.0 | -14.3 |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Eterna Therapeutics Inc (ERNA)
| -72.8 | -83.4 | -44.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Eterna Therapeutics Inc (ERNA)
|
0.2 | 5.6 | 0.0 | -14.1 | -- | -687.5 | -- | 2.3 |
| 73.9 | 10,349.8 | 1,091.0 | 202.3 | 31.6 | 31.3 | 46.2 | 18.2 | |
| 229.3 | 14,164.2 | 691.7 | -219.0 | -13.7 | 163.2 | -- | 78.1 | |
| 65.3 | 8,115.2 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 44.9 | 11,415.1 | 2,320.1 | 782.6 | 39.0 | 35.5 | 16.2 | 5.3 | |
| 88.9 | 11,662.4 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 512.4 | 11,754.2 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 19.5 | |
| 410.5 | 11,724.9 | 2,678.3 | 460.4 | 21.1 | 103.2 | 25.9 | 19.6 | |
| 104.5 | 8,215.5 | 0.0 | -425.4 | -- | -36.7 | -- | 6.6 | |
| 344.8 | 9,603.5 | 0.0 | -303.3 | -- | -45.8 | -- | 10.9 |
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic... pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts. Read more
Principal Financial & Accounting Officer and Senior VP of Finance
Ms. Sandra M. Gurrola
Principal Financial & Accounting Officer and Senior VP of Finance
Ms. Sandra M. Gurrola
Headquarters
Cambridge, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Eterna Therapeutics Inc (ERNA) is $0.19 (NASDAQ) as of 24-Apr-2026 16:00 EDT. Eterna Therapeutics Inc (ERNA) has given a return of -84.28% in the last 3 years.
Since, TTM earnings of Eterna Therapeutics Inc (ERNA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-0.51
|
3.00
|
|
2024
|
-0.01
|
0.17
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
--
|
--
|
The 52-week high and low of Eterna Therapeutics Inc (ERNA) are Rs 4.02 and Rs 0.18 as of 26-Apr-2026.
Eterna Therapeutics Inc (ERNA) has a market capitalisation of $ 6 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Eterna Therapeutics Inc (ERNA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.